Indian Emulsifiers Ltd H1FY26 Concall Decoded – From Lab Coats to Rocket Growth (55% YoY Revenue Burst!)

1. Opening Hook

When a chemical company starts sounding like a SaaS startup, you know it’s cooking something potent. Indian Emulsifiers just pulled off a 55% revenue surge and a 63% jump in PAT, all while its Aussie baby started making noise down under. The MD coughed once but flexed twice—new capacity, new land, new products, and even new continents. It’s not chemistry; it’s alchemy.

And before you think that’s it—wait till you see how they’re funding it (hint: not your usual debt). Stick around, the plot thickens faster than their emulsions. 😏

2. At a Glance

• Revenue up 55%: CFO swears it’s operational excellence, not chemical reaction.
• PAT up 63%: Profits bubbling like a beaker on full flame.
• EBITDA Margin 19–22%: Stable—because chemistry loves equilibrium.
• Receivables doubled to ₹58 crore: Customers love the product… maybe too much credit.
• Rights issue at ₹80: A 50% discount—call it “liquidity emulsified.”
• Capacity up 150%: Reactors, not reactors—expansion without explosion.

3. Management’s Key Commentary

“Revenue stood at ₹76.98 crore, up 55%. PAT grew 63%.”
(Translation: The lab finally turned into a money-printing machine.)

“Our Australian subsidiary executed its first order.”
(Aussies finally said “G’day” to emulsions; mining explosives just got smoother.)

“Phase one CapEx funded via equity; phase two will use debt.”
(Read: dilute first, borrow later—the hybrid workout plan for balance sheets.)

“Debtor days average 115–120.”
(Translation: Our customers take their sweet chemical time paying us.)

“Capacity expanded to 1,000 MT, targeting 90%+ utilization soon.”
(They’re turning up the burners, literally.)

“EBITDA margins steady at 19–22%, expect continuation.”
(Steady margins—unlike the company’s expansion curve, which is vertical.)

“Australian ops to deliver ₹75 crore in 36 months.”
(A small step for Sydney, a giant leap for Indian Emulsifiers.) 🧪

4. Numbers Decoded